Product
CA-4948
3 clinical trials
6 indications
Indication
Stomach CancerIndication
Esophageal cancerIndication
Esophageal CancerIndication
Melanoma Metastatic in the BrainIndication
Myelodysplastic SyndromesIndication
AnaemiaClinical trial
Phase I Trial of CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal CancerStatus: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Phase 1/2 Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab Following Stereotactic Radiosurgery in Patients With Melanoma Brain MetastasesStatus: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Phase II, Open-Label, Multicenter Study of Orally Administered CA-4948 for the Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS)Status: Terminated, Estimated PCD: 2024-03-06